Variational AI discovers small molecules based on customer-defind properties and then licenses or transfers lead candidates to the customers to further develop. They implemented Variational Autoencoders (VAE) model for molecular de novo design and target identification, validation and hit discovery.
- Drug Candidate as a Service (DCaaS)
- Software as a Service / AI as Service (SaaS, AIaaS)
- Chemical notations and molecular fingerprints
- Small molecules
- Lead Discovery